Summary
In patients with relapsing multiple sclerosis who participated in the TRANSFORMS trial, magnetic resonance imaging activity and relapses in the first year predicted clinical outcomes over 3 years of the extension trial. Switching from interferon beta-1a to fingolimod at 12 months reduced the proportion of patients with focal magnetic resonance imaging activity and relapse by 70%.
- fingolimod
- multiple sclerosis
- relapse
- focal MRI
- TRANSFORMS
- NCT00340834
- extension
- interferon beta-1a
- neurology clinical trials
- demyelinating diseases
- © 2015 SAGE Publications
Tools
Disease Activity in Year 1 Predicts Long-term Outcomes in Patients Taking Fingolimod
Permalink:
Table of contents
Cited By...
- No citing articles found.